Sterilization with Cobalt Radiation of Fascia Lata for Homotransplant* *From the Department of Ophthalmology, University Hospital, Ann Arbor, Michigan.

1965 ◽  
Vol 59 (6) ◽  
pp. 1095-1098 ◽  
Author(s):  
Froncie A. Gutman
Keyword(s):  
Fascia Lata ◽  
University Hospital ◽  
Department Of Ophthalmology ◽  
Ann Arbor ◽  
Cobalt Radiation

Impact Of Dose-Density Delays In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-CHOP21 Or R-CHOP14

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4374-4374
Author(s):  
Antonio Gutierrez ◽  
Antonia M Bautista-Gili ◽  
Leyre Bento ◽  
Ines Herraez ◽  
Lucia Garcia ◽  
...  
Keyword(s):  
Conflicts Of Interest ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
University Hospital ◽  
Aggressive Lymphoma ◽  
High Dose ◽  
Prognostic Impact ◽  
Non Hodgkin Lymphoma ◽  
Ann Arbor ◽  
The Impact

Abstract Background DLBCL is the more common non Hodgkin lymphoma. This is an aggressive lymphoma that is treated with a standard chemotherapy regimen: R-CHOP. In the last years attempts have been done to improve the outcome both increasing dose-density (DD) (CHOP14) or intensity (CHOEP, ACVBP, frontline high dose therapy followed by autologous stem cell transplantation). Although phase 2 studies of these interventions suggested promising results, when randomized phase 3 trials have been conducted, there is no demonstrated benefit of these higher toxicity approaches when compared with R-CHOP alone. Only addition of rituximab to CHOP has proved a survival advantage. This has allowed setting R-CHOP administered every 21 days (R-CHOP21) as the standard treatment for DLBCL patients. The purpose of this study is further analyzing the prognostic impact of DD delays in two cohorts of DLBCL patients treated with R-CHOP21 or R-CHOP14. Methods All patients diagnosed between 1999 and 2013 of DLBCL in University Hospital Son Espases were identified from Pathology Department registry. Only patients treated with R-CHOP21 or R-CHOP14 +/- radiotherapy were included. Patients receiving other chemotherapy regimens or consolidations were excluded. DD delay was calculated as follows: DD delay = real number of days from first to last cycle of chemotherapy / expected number of days from first to last cycle in every regimen. Results A total of 166 cases were identified: considering inclusion and exclusion criteria finally 111 cases were selected (71 in the R-CHOP21 cohort and 40 in the R-CHOP14 cohort). Respectively for R-CHOP21 and R-CHOP14, 61% and 37% were older than 60 years (p=0.02), 26% and 35% had an ECOG PS higher than 1 (p=0.3), 49% and 62% had an Ann Arbor stage III-IV (p=0.09), 44% and 51% an a-IPI higher than 1 (p=0.47). Median DD delay was 2% versus 14% for R-CHOP21 and R-CHOP14 groups (p<0.001). Clinically significant DD delay was considered those patients with DD delay higher than the median of the R-CHOP14 group. Complete response (CR) rate in patients with or without DD delay higher than 14% was 50% versus 85% in the R-CHOP21 group (p=0.004) and 80% versus 78% for R-CHOP14 group (p=0.87). Median follow-up was 60 months (4-169). OS and PFS were not significantly different in patients treated with R-CHOP21 or R-CHOP14: respectively 5y-OS of 73% vs 82% (p=0.97) and 5y-PFS 78% vs 70% (p=0.46). However, DD delay higher than 14% influenced OS and PFS only in the R-CHOP21 group (5y-OS of 39% vs 82% with or without DD delay; p=0.002 and 5y-PFS of 61% versus 81%; p=0.024) but not in the R-CHOP14 group (5y-OS of 78% vs 84% with or without DD delay; p=0.24 and 5y-PFS of 57% versus 72%; p=0.56). Conclusions Overall in our series there were no differences in terms of response or survival between patients treated with R-CHOP21 or R-CHOP14. Significantly higher rates of DD delay were observed in the R-CHOP14 group. However, the impact of DD delays on response and survival was only observed in the R-CHOP21 group but not in patients treated with R-CHOP14. We can conclude that R-CHOP21 and R-CHOP14 are equivalent regimens in terms of response and survival only if DD delays are avoided. For patients receiving R-CHOP21 we recommend using clinical and support measures in order to avoid DD delays. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Patients’ perception of the open-space operating hall for cataract surgery

2019 ◽  
Author(s):  
Maxime ENJARY ◽  
Dominique MONNET ◽  
Clémence BONNET ◽  
Antoine BREZIN
Keyword(s):  
Prospective Study ◽  
Cataract Surgery ◽  
Open Space ◽  
Ethics Committee ◽  
Topical Anesthesia ◽  
University Hospital ◽  
French Society ◽  
Ophthalmic Surgery ◽  
Face To Face ◽  
Department Of Ophthalmology

Abstract Background : The purpose of this study was to assess the perception of patients undergoing cataract surgery under topical anesthesia in an open-space operating hall. The study was set in the Department of Ophthalmology, Cochin Paris Descartes University Hospital, in a newly built open-space operating hall dedicated to ophthalmic surgery. Methods: 250 consecutive patients undergoing cataract surgery by 11 surgeons were included in this prospective study. All the included patients have been operated in an open-space operating hall with 3 surgical areas. Only first-eye standard cataract surgeries performed under topical anesthesia were included. Responses to a face-to-face questionnaire administered by a single interviewer to patients before their discharge on the day of their surgery were analyzed. Results: Fifty-two patients (21%) knew beforehand that their procedure would take place in an open-space operating hall, 118 (47%) realized that they were in such an environment on the occasion of their surgery and 80 (32%) did not notice. Conversations and noises unrelated to their own surgeries were overheard respectively by 15 (6%) and 37 (15%) patients. Of the 250 patients, 237 (95%) did not report any discomfort associated with the fact that their procedure had been performed in an open-space operating hall. Conclusions: Cataract surgery performed in an open-space setting did not seem to affect the patients’ comfort during the procedure. Trial registration : This manuscript has been retrospectively registered and approved in 9 october 2018 by the Ethics Committee of the French Society of Ophthalmology (IRB 00008855 Société Française d’Ophtalmologie IRB#1) because the Committee did not find any challenge against the medical and scientific rules of ethics, as accepted in France.

scholarly journals Aflibercept for Vascularised Serous Pigment Epithelial Detachment: One-Year Anatomical and Functional Results

2020 ◽  
Vol 76 (2) ◽  
pp. 88-93
Author(s):  
Jaroslav Románek ◽  
Hana Palyzová ◽  
Jan Grygar ◽  
Jan Ernest
Keyword(s):  
Visual Acuity ◽  
Functional Results ◽  
University Hospital ◽  
Pigment Epithelial Detachment ◽  
Intravitreal Therapy ◽  
Pigment Epithelial ◽  
Department Of Ophthalmology ◽  
Treatment Naïve ◽  
One Year ◽  
The Military

Purpose: To assess the effect of intravitreal aflibercept on pigment epithelial detachment (PED) secondary to occult choroidal neovascularization (CNV) in treatment-naive patients. Patients and methods: Retrospective analysis of thirty-six patients (thirty-eight eyes) with mean age 77 (SD ± 7), who were treated with aflibercept 2.0 mg (Eylea, Bayer) at the Department of Ophthalmology of 1st Faculty of Medicine of the Charles University and the Military University Hospital Prague. All patients were treated in fixed regimen, which means 3 loading doases 1 month apart, followed by further 2-monthly doses over total 12-month period. Best corrected visual acuity (BCVA) was evaluated on Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Diameters as PED height, width and central retinal thickness (CRT) were assesed using spectral-domain optical coherence tomography. All previously mentioned were analyzed et the baseline and than at every visit. Therapy complications were also evaluated. Results: Borderline significant improvement in the mean of BCVA score of 3.2 letters (SD ± 11.6, p = 0.05) at the end of follow-up period was observed. Mean PED height at 12 months significantly decreased by 140 µm (SD ± 238, p < 0.01). Reductions in PED height were correlated with reductions in central macular thickness (R = 0.94, p < 0.001) simultaneously with PED width (R = 0.45, p < 0.01). There was no significant correlation between PED height decrease and visual acuity. PED rupture was observed in 3 eyes (8 %). Conclusion: Aflibercept intravitreal therapy in fixed regimen in patients with PED secondary to occult CNV shows great anatomical effect. However, correlation between PED diameters and visual acuity was not observed.

Safety of Intravitreal Injection Guide

2017 ◽  
Vol 2 (1) ◽  
pp. 26-31
Author(s):  
Kei Watanabe ◽  
Uematsu Masafumi ◽  
Yasser H. Mohamed ◽  
Takehito Watanabe ◽  
Yusuke Doi ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
University Hospital ◽  
Vascular Endothelial ◽  
Drug Usage ◽  
Anti Vegf ◽  
Systemic Complication ◽  
Department Of Ophthalmology ◽  
Significant Difference ◽  
Period Data ◽  
Endothelial Growth Factor

Purpose: To evaluate the safety of our developed intravitreal injection guide. Methods: Retrospective review of all case notes for consecutive patients treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections at the Department of Ophthalmology, Nagasaki University Hospital in Japan between January 2013 and December 2014. We included all patients who had at least 1 intravitreal anti-VEGF injection done within the study period. Data collected included demographics, indications of intravitreal anti-VEGF injections, type of injected drug, usage of intravitreal guide, experience of physicians, and any complication that occurred during or after the procedure. Results: The study included 256 patients (154 males and 102 females) who underwent 992 intravitreal anti-VEGF injections from January 2013 until December 2014. The mean age of the patients was 70.8 ± 11.3 years. Of total injections, 907 (91.44%) were done using the intravitreal guide, 60 (6.04%) were done without using the guide, and only 25 (2.52%) injections were not determined. Local complications include 1 (0.1%) case uveitis, 1 (0.1%) case retinal tear, and 1 (0.1%) case amaurosis fugax. There were no major complications as cataract, retinal detachment, and endophthamitis. No systemic complication was encountered. All complications occurred in the guide group without statistically significant difference in comparison to without guide group ( P = 1.0). All complications were related to experienced group without significant difference in comparison to limited experienced group ( P = .28). Conclusion: We conclude that the process of intravitreal injection with our developed intravitreal injection guide is safe and easy even for limited experienced physicians.

Sign in / Sign up

Export Citation Format

Share Document